Lamivudine
Lamivudine is an antiviral medicine (a nucleoside analogue) used with other antiretrovirals to treat HIV-1 infection, and in a separate lower-dose tablet to treat chronic hepatitis B virus (HBV) infection.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 20 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Lamivudine is an antiviral that blocks the enzyme HIV and hepatitis B use to copy themselves, taken with other medicines for HIV-1 and, as a separate tablet, for chronic hepatitis B; around since about 1995 and available as a generic, it is a mainstay of HIV treatment. Most people tolerate it very well; headache, nausea or tiredness are the usual complaints. The boxed warning covers potentially fatal lactic acidosis (acid buildup in the blood) with a fatty, enlarged liver, severe hepatitis B flares after stopping, and mix-ups between the HIV and lower-dose hepatitis B tablets, so take only the form prescribed for you and never stop on your own.
Clinical pearls
- Sorbitol, a sweetener in some liquid medicines, can lower lamivudine levels, so avoid taking sorbitol-containing liquids regularly alongside it.
- Kidney function sets the dose, so tell every prescriber about kidney problems and expect a dose change if function drops.
- In children, report belly pain with nausea or vomiting promptly, since suspected pancreatitis means stopping lamivudine right away.
- If you have hepatitis B and lamivudine is ever stopped, plan on liver blood tests for at least several months afterward.
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
Lamivudine can cause lactic acidosis and severe liver enlargement with fat buildup, and these can be fatal. Your doctor may stop it if lab results or symptoms suggest this.
If you have both HIV-1 and hepatitis B and you stop lamivudine, your hepatitis B can flare severely. Your liver should be monitored closely for at least several months after stopping.
Lamivudine HIV tablets and lamivudine HBV tablets contain different amounts of the medicine. People with HIV-1 should take only the form made for HIV-1.
Patient information guide A plain-language walkthrough of Lamivudine, written from its FDA label.
What Lamivudine is used for
▾
Lamivudine treats viral infections, with different products for different viruses.
- HIV-1 infection: Epivir tablets and oral solution, lamivudine oral solution and lamivudine tablets are used with other antiretroviral medicines.
- Chronic hepatitis B (HBV): lamivudine tablets (HBV) are used when there is viral replication and active liver inflammation.
- The HBV tablets should only be considered when an alternative antiviral with a higher barrier to resistance is not available or appropriate.
- The HBV tablets have not been studied in people also infected with HIV, hepatitis C or hepatitis delta, in liver transplant recipients, or in decompensated liver disease.
How Lamivudine works
▾
Lamivudine is a nucleoside analogue reverse transcriptase inhibitor, a type of antiretroviral medicine. It works against the virus to help treat the infection. For HIV-1, it is always combined with other antiretroviral medicines.
Resistant virus can develop. This has been seen with hepatitis B virus in people on lamivudine, including people with HIV-1 and HBV.
Lamivudine dosage
▾
Lamivudine for HIV-1 is taken by mouth, once or twice daily, with or without food. Children's doses depend on weight, and kidney problems require dose changes.
- Epivir scored tablets are preferred for children weighing at least 14 kg who can swallow tablets.
- The oral solution is for children who cannot safely swallow tablets.
- Do not switch between HIV and HBV tablets. Follow your prescriber's instructions.
Dosing details from the FDA-approved label
From the Lamivudine prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Adults (HIV-1-infected)
- 300 mg daily, administered as either 150 mg taken orally twice daily or 300 mg taken orally once daily with or without food
- If administered to a patient infected with HIV-1 and HBV, the dosage indicated for HIV-1 therapy should be used as part of an appropriate combination regimen
- Pediatric patients aged 3 months and older (HIV-1-infected)
- Administered either once or twice daily
- Dose should be calculated on body weight (kg)
- Maximum: should not exceed 300 mg daily
- Scored tablet is preferred for patients who weigh at least 14 kg and can swallow tablets; oral solution may be prescribed for patients unable to safely and reliably swallow tablets
- Patients with renal impairment
- Doses of EPIVIR must be adjusted in accordance with renal function
- Adjusted according to renal function
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION Adults: 300 mg daily, administered as either 150 mg twice daily or 300 mg once daily. (2.1) Pediatric Patients Aged 3 Months and Older: Administered twice daily. Dose should be calculated on body weight (kg) and should not exceed 300 mg daily. (2.2) Patients with Renal Impairment: Doses of LAMIVUDINE must be adjusted in accordance with renal function. (2.3) 2.1 Recommended Dosage for Adult Patients The recommended dosage of LAMIVUDINE in HIV-1-infected adults is 300 mg daily, administered as either 150 mg taken orally twice daily or 300 mg taken orally once daily with or without food. If lamivudine is administered to a patient infected with HIV-1 and HBV, the dosage indicated for HIV-1 therapy should be used as part of an appropriate combination regimen [see Warnings and Precautions (5.2) ]. 2.2 Recommended Dosage for Pediatric Patients The recommended dosage of EPIVIR oral solution in HIV-1-infected pediatric patients aged 3 months and older is 4 mg per kg taken orally twice daily (up to a maximum of 300 mg daily), administered in combination with other antiretroviral agents. Once daily dosing in pediatric patients 3 months of age and older in combination with other antiretroviral agents for the treatment of HIV-1 infection. LAMIVUDINE scored tablet is the preferred formulation for HIV-1-infected pediatric patients who weigh at least 14 kg and for whom a solid dosage form is appropriate. Before prescribing LAMIVUDINE scored tablets, pediatric patients should be assessed for the ability to swallow tablets. For patients unable to safely and reliably swallow LAMIVUDINE tablets, the oral solution formulation should be prescribed [see Warnings and Precautions (5.6) ] . The recommended oral dosage of LAMIVUDINE tablets for HIV-l-infected pediatric patients is presented in Table 1. Table 1. Dosing Recommendations for LAMIVUDINE Scored (150-mg) Tablets in Pediatric Patients Weight (kg) Twice-daily Dosing Regimen Using Scored 150-mg Tablet AM Dose PM Dose Total Daily Dose 14 to <20 ½ tablet (75 mg) ½ tablet (75 mg) 150 mg ≥20to <25 ½ tablet (75 mg) 1 tablet (150 mg) 225 mg ≥25 1 tablet (150 mg) 1 tablet (150 mg) 300 mg Additional pediatric use information for patients aged 3 months and above is approved for ViiV Healthcare Company’s EPIVIR® (lamivudine) tablets and oral solution.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Lamivudine side effects
▾
The most common side effects in adults are:
Common side effects
- Headache
- Nausea
- Tiredness and a general unwell feeling (malaise)
- Stuffy or runny nose
- Diarrhea
- Cough
- Fever (more common in children)
When to get medical help
- Call your doctor right away if you have signs of lactic acidosis or liver problems. Lactic acidosis is a buildup of acid in the blood, and liver problems can include an enlarged liver with fat buildup. Lamivudine may need to be stopped.
- Call your doctor if you have hepatitis B and stop lamivudine. Hepatitis can flare up, and sometimes it is severe.
- Get help for signs of pancreatitis (inflammation of the pancreas), especially in children. Treatment should be stopped right away if it is suspected.
- Seek urgent help for an allergic reaction such as hives or anaphylaxis. These have been reported after approval.
- Tell your doctor about new inflammation or infection symptoms after starting HIV treatment. This may be immune reconstitution syndrome.
- Report muscle weakness or severe anemia symptoms. Both have been reported after approval.
Lamivudine warnings and precautions
▾
- Lactic acidosis and severe liver enlargement can be fatal. Most cases were in women.
- Hepatitis B flare after stopping: monitor for at least several months.
- Wrong product: using HBV tablets for HIV-1 can quickly cause HIV resistance.
- Pancreatitis in children, which can be fatal.
- Hepatitis C with interferon and ribavirin: risk of liver decompensation.
- Immune reconstitution syndrome and body fat changes can occur with HIV therapy.
Lamivudine interactions
▾
A few things can change how lamivudine works or how safe it is.
- Sorbitol: lowers lamivudine levels in a dose-dependent way, so avoid regular use together.
- Trimethoprim and similar drugs: they are cleared by the same kidney pathway.
- Interferon alfa and ribavirin: raise concern for liver decompensation in people with HIV-1 and hepatitis C.
Interactions listed in the FDA-approved label
From the Lamivudine prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Sorbitol: Coadministration of single doses of lamivudine and sorbitol resulted in a sorbitol dose-dependent reduction in lamivudine exposures. When possible, avoid use of sorbitol-containing medicines with lamivudine; when possible, avoid chronic coadministration.
- Drugs eliminated by active renal secretion via the organic cationic transport system (e.g., trimethoprim): Lamivudine is predominantly eliminated in the urine by active organic cationic secretion, so the possibility of interactions with such drugs should be considered. No data are available regarding interactions with other drugs that have renal clearance mechanisms similar to that of lamivudine.
Read the label’s full interactions text
7 DRUG INTERACTIONS Sorbitol: Coadministration of lamivudine and sorbitol may decrease lamivudine concentrations; when possible, avoid chronic coadministration. ( 7.2 ) 7.1 Drugs Inhibiting Organic Cation Transporters Lamivudine is predominantly eliminated in the urine by active organic cationic secretion. The possibility of interactions with other drugs administered concurrently should be considered, particularly when their main route of elimination is active renal secretion via the organic cationic transport system (e.g., trimethoprim) [see Clinical Pharmacology ( 12.3 )] . No data are available regarding interactions with other drugs that have renal clearance mechanisms similar to that of lamivudine. 7.2 Sorbitol Coadministration of single doses of lamivudine and sorbitol resulted in a sorbitol dose-dependent reduction in lamivudine exposures. When possible, avoid use of sorbitol-containing medicines with lamivudine [see Warnings and Precautions ( 5.5 ), Clinical Pharmacology ( 12.3 )] .
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Lamivudine
▾
- Do not use if you previously had a hypersensitivity reaction to lamivudine.
- Tell your doctor about liver disease, hepatitis B or hepatitis C.
- Kidney impairment requires a lower dose.
- Children with a history of pancreatitis need caution.
- Women with HIV should not breastfeed.
- Pregnancy registry data showed no increase in overall birth defects.
- Older adults may be more likely to have reduced organ function.
Lamivudine overdose
▾
There is no known specific treatment for lamivudine overdose. The person should be monitored and given standard supportive care. Dialysis removed very little lamivudine, so its benefit is unknown.
How your body processes Lamivudine
▾
Lamivudine is well absorbed by mouth, with about 86 to 87% reaching the bloodstream from the tablet or oral solution. Little is broken down by the body. Most leaves unchanged in the urine, and the half-life is about 5 to 7 hours. Kidney problems affect how it is cleared, which is why dose adjustment is needed.
How to store Lamivudine
▾
Store EPIVIR tablets at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) . Store in tightly closed bottles at 25°C (77°F) .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Lamivudine
18 supplements and herbal products have documented interactions with Lamivudine in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 1
- Moderate · 8
- Minor · 9
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Lamivudine: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Lamivudine — the kind of thing our pharmacy team would talk through with you at the counter.
What is lamivudine for?
▾
How do I take it?
▾
What side effects should I expect?
▾
Can I stop it if I feel fine?
▾
Do I need to avoid any other medicines?
▾
Is it safe in pregnancy?
▾
Is Lamivudine available over the counter?
▾
When was Lamivudine first available?
▾
Who makes Lamivudine?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Lamivudine on HelloPharmacist
Lamivudine forms and strengths (how it comes)
Lamivudine is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Lamivudine inactive ingredients by manufacturer.
Tablet
How this form is used
- Epivir and Lamivudine tablets for HIV-1 are used with other antiretrovirals to treat HIV-1 infection.
- Lamivudine tablets (HBV) are used for chronic HBV infection with viral replication and active liver inflammation.
- Epivir and Lamivudine HIV-1 tablets are not for treating HBV.
- Adults can take Epivir tablets with or without food, once or twice daily as prescribed.
- Epivir scored tablets are the preferred form for HIV-1 children weighing at least 14 kg who can swallow tablets.
- Patients with HIV-1 should take only lamivudine tablets made for HIV-1, not the HBV tablets.
Oral solution
How this form is used
- Epivir and lamivudine oral solution are used with other antiretrovirals to treat HIV-1 infection.
- Epivir and lamivudine oral solution are not for treating HBV.
- Lamivudine oral solution may be taken with or without food.
- Epivir oral solution may be prescribed for children who cannot safely and reliably swallow tablets.
- Lamivudine oral solution used with other antiretroviral oral solutions was linked to lower viral suppression in children, so more frequent viral load monitoring may be considered.
Lamivudine on the U.S. market: products, makers and brands
How Lamivudine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
15 companies list 29 Lamivudine product records with the FDA, mostly as tablet, oral solution; the earliest marketing or approval year on record is 1995. Brand names on the directory include Epivir-HBV, Epivir; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (16) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Lamivudine is used (Medicaid data)
A general measure of how commonly Lamivudine is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Lamivudine is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Lamivudine prescribed? Of the 1,601 medications we measure, Lamivudine ranks #1,038 by Medicaid prescriptions — more than 35% of them.
Utilization by Lamivudine product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
lamivudine 300 MG Oral Tablet Most dispensed
Summed across the 3 of 20 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 349491
lamivudine 100 MG Oral Tablet
Summed across the 1 of 11 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 205328
lamivudine 150 MG Oral Tablet
Summed across the 3 of 33 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 199147
lamivudine 10 MG/ML Oral Solution
Summed across the 2 of 10 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 199148
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Lamivudine, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 9 of 74 listed Lamivudine NDCs with Medicaid activity.
Compare Lamivudine products
A representative set of FDA-listed product records for Lamivudine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Oral solution | ||||
| 10 mg/mL | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 10 mg/mL | Oral | Chartwell Govermental & Specialty RX, LLC. | ANDA | View NDC → |
| 10 mg/mL | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 10 mg/mL | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 10 mg/mL | Oral | ViiV Healthcare Company | NDA | View NDC → |
| 💊Tablet | ||||
| 150 mg | Oral | American Health Packaging | ANDA | View NDC → |
| 100 mg | Oral | Apotex Corp. | ANDA | View NDC → |
| 150 mg | Oral | Apotex Corp. | ANDA | View NDC → |
| 300 mg | Oral | Apotex Corp. | ANDA | View NDC → |
| 150 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 300 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 100 mg | Oral | Camber Pharmaceuticals, Inc. × 2 listings | ANDA | View NDC → |
| 150 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 300 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 150 mg | Oral | Coupler LLC | ANDA | View NDC → |
| 100 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 150 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 300 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 150 mg | Oral | Ingenus Pharmaceuticals, LLC | ANDA | View NDC → |
| 300 mg | Oral | Ingenus Pharmaceuticals, LLC | ANDA | View NDC → |
| 150 mg | Oral | Lupin Pharmaceuticals, Inc. | ANDA | View NDC → |
| 150 mg | Oral | Macleods Pharmaceuticals Limited | ANDA | View NDC → |
| 300 mg | Oral | Macleods Pharmaceuticals Limited | ANDA | View NDC → |
| 150 mg | Oral | Major Pharmaceuticals | ANDA | View NDC → |
| 150 mg | Oral | Strides Pharma Science Limited | ANDA | View NDC → |
| 300 mg | Oral | Strides Pharma Science Limited | ANDA | View NDC → |
| 150 mg | Oral | ViiV Healthcare Company | NDA | View NDC → |
| 300 mg | Oral | ViiV Healthcare Company | NDA | View NDC → |
Showing 29 of 29 products — FDA National Drug Code Directory. See every product, package size and price: browse all 29 Lamivudine NDCs →
Lamivudine side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Lamivudine — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Lamivudine in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Lamivudine FDA approval history
How Lamivudine went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Lamivudine recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Lamivudine recalls since July 2021.
✅No Lamivudine recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 68244 2 dose forms · 5 strengths
-
Dose form (SCDF) Oral Solution RxCUI 372562In current FDA listings -
Dose form (SCDF) Oral Tablet RxCUI 372563In current FDA listings
Look up RxCUI 68244 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Lamivudine supply and shortage status
Whether Lamivudine is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Lamivudine costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Tablet, Film Coated · Oral | 150 mg | $0.489 per tablet | NDC details & price history |
| Tablet, Film Coated · Oral | 300 mg | $1.29 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Lamivudine brand names
Lamivudine is sold under 2 brand names in the FDA directory — Epivir-HBV, Epivir. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Lamivudine: manufacturers and labelers
15 companies list Lamivudine products with the FDA. By number of product records, the largest are Camber Pharmaceuticals, Inc., Apotex Corp., Aurobindo Pharma Limited. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Lamivudine drug class (RxNorm)
Lamivudine belongs to the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Lamivudine page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. ViiV Healthcare Company is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →